Key facts
- It has raised $1.0M; the latest was Seed Round in Jan 2026.
- Notable investors include Mirae Science and Technology.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cellknit
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellknit are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellknit
Developer of a cell delivery technology designed to improve the efficiency and viability of cell therapy applications. The company leverages biomimetic nanoweaving combined with semiconductor and fiber engineering for minimally invasive, needle-based cell delivery to reduce cell loss, improve survival rates, accelerate therapeutic onset, early commercial validation, and alignment with regulatory pathways for pre-clinical treatment and reimbursement, enabling medical researchers and clinical practitioners to increase cellular survival rates and facilitate localized integration within complex biological environments.
- Sector
- Healthcare
- HQ
- Pohang, South Korea
- Founded
- 2024
- Employees
- 2
- Website
- cellknit.com/
- Ownership
- Privately Held (backing)
Cellknit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellknit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellknit in its N-PORT filings yet. We sweep new filings monthly.